Abstract
A certain number of studies were carried out to address the question of how dysbiosis could affect the onset and development of rheumatoid arthritis (RA), but little is known about the reciprocal influence between microbiota composition and immunosuppressive drugs, and how this interaction may have an impact on the clinical outcome. The aim of this study was to characterize the intestinal microbiota in a groups of RA patients treatment-naïve, under methotrexate, and/or etanercept (ETN). Correlations between the gut microbiota composition and validated immunological and clinical parameters of disease activity were also evaluated. In the current study, a 16S analysis was employed to explore the gut microbiota of 42 patients affected by RA and 10 healthy controls. Disease activity score on 28 joints (DAS-28), erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, anti-cyclic citrullinated peptides, and dietary and smoking habits were assessed. The composition of the gut microbiota in RA patients free of therapy is characterized by several abnormalities compared to healthy controls. Gut dysbiosis in RA patients is associated with different serological and clinical parameters; in particular, the phylum of Euryarchaeota was directly correlated to DAS and emerged as an independent risk factor. Patients under treatment with ETN present a partial restoration of a beneficial microbiota. The results of our study confirm that gut dysbiosis is a hallmark of the disease, and shows, for the first time, that the anti-tumor necrosis factor alpha (TNF-α) ETN is able to modify microbial communities, at least partially restoring a beneficial microbiota.
| Original language | English |
|---|---|
| Article number | 2938 |
| Journal | International Journal of Molecular Sciences |
| Volume | 19 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Oct 1 2018 |
Fingerprint
Keywords
- Anti-TNF-α
- Disease activity
- Etanercept
- Methotrexate
- Microbiota
- Rheumatoid arthritis
ASJC Scopus subject areas
- Catalysis
- Molecular Biology
- Spectroscopy
- Computer Science Applications
- Physical and Theoretical Chemistry
- Organic Chemistry
- Inorganic Chemistry
Cite this
Analysis of gut microbiota in rheumatoid arthritis patients : Disease-related dysbiosis and modifications induced by etanercept. / Picchianti-Diamanti, Andrea; Panebianco, Concetta; Salemi, Simonetta; Sorgi, Maria Laura; Di Rosa, Roberta; Tropea, Alessandro; Sgrulletti, Mayla; Salerno, Gerardo; Terracciano, Fulvia; D’amelio, Raffaele; Laganà, Bruno; Pazienza, Valerio.
In: International Journal of Molecular Sciences, Vol. 19, No. 10, 2938, 01.10.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Analysis of gut microbiota in rheumatoid arthritis patients
T2 - Disease-related dysbiosis and modifications induced by etanercept
AU - Picchianti-Diamanti, Andrea
AU - Panebianco, Concetta
AU - Salemi, Simonetta
AU - Sorgi, Maria Laura
AU - Di Rosa, Roberta
AU - Tropea, Alessandro
AU - Sgrulletti, Mayla
AU - Salerno, Gerardo
AU - Terracciano, Fulvia
AU - D’amelio, Raffaele
AU - Laganà, Bruno
AU - Pazienza, Valerio
PY - 2018/10/1
Y1 - 2018/10/1
N2 - A certain number of studies were carried out to address the question of how dysbiosis could affect the onset and development of rheumatoid arthritis (RA), but little is known about the reciprocal influence between microbiota composition and immunosuppressive drugs, and how this interaction may have an impact on the clinical outcome. The aim of this study was to characterize the intestinal microbiota in a groups of RA patients treatment-naïve, under methotrexate, and/or etanercept (ETN). Correlations between the gut microbiota composition and validated immunological and clinical parameters of disease activity were also evaluated. In the current study, a 16S analysis was employed to explore the gut microbiota of 42 patients affected by RA and 10 healthy controls. Disease activity score on 28 joints (DAS-28), erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, anti-cyclic citrullinated peptides, and dietary and smoking habits were assessed. The composition of the gut microbiota in RA patients free of therapy is characterized by several abnormalities compared to healthy controls. Gut dysbiosis in RA patients is associated with different serological and clinical parameters; in particular, the phylum of Euryarchaeota was directly correlated to DAS and emerged as an independent risk factor. Patients under treatment with ETN present a partial restoration of a beneficial microbiota. The results of our study confirm that gut dysbiosis is a hallmark of the disease, and shows, for the first time, that the anti-tumor necrosis factor alpha (TNF-α) ETN is able to modify microbial communities, at least partially restoring a beneficial microbiota.
AB - A certain number of studies were carried out to address the question of how dysbiosis could affect the onset and development of rheumatoid arthritis (RA), but little is known about the reciprocal influence between microbiota composition and immunosuppressive drugs, and how this interaction may have an impact on the clinical outcome. The aim of this study was to characterize the intestinal microbiota in a groups of RA patients treatment-naïve, under methotrexate, and/or etanercept (ETN). Correlations between the gut microbiota composition and validated immunological and clinical parameters of disease activity were also evaluated. In the current study, a 16S analysis was employed to explore the gut microbiota of 42 patients affected by RA and 10 healthy controls. Disease activity score on 28 joints (DAS-28), erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, anti-cyclic citrullinated peptides, and dietary and smoking habits were assessed. The composition of the gut microbiota in RA patients free of therapy is characterized by several abnormalities compared to healthy controls. Gut dysbiosis in RA patients is associated with different serological and clinical parameters; in particular, the phylum of Euryarchaeota was directly correlated to DAS and emerged as an independent risk factor. Patients under treatment with ETN present a partial restoration of a beneficial microbiota. The results of our study confirm that gut dysbiosis is a hallmark of the disease, and shows, for the first time, that the anti-tumor necrosis factor alpha (TNF-α) ETN is able to modify microbial communities, at least partially restoring a beneficial microbiota.
KW - Anti-TNF-α
KW - Disease activity
KW - Etanercept
KW - Methotrexate
KW - Microbiota
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=85054496085&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054496085&partnerID=8YFLogxK
U2 - 10.3390/ijms19102938
DO - 10.3390/ijms19102938
M3 - Article
C2 - 30261687
AN - SCOPUS:85054496085
VL - 19
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
SN - 1661-6596
IS - 10
M1 - 2938
ER -